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Influenza-virus antigenicity evolves to escape host
immune protection. Antibody lineages within individ-
uals evolve in turn to increase affinity and hence po-
tency. Strategies for a ‘‘universal’’ influenza vaccine
to elicit lineages that escape this evolutionary arms
race and protect against seasonal variation and
novel, pandemic viruses will require directing B cell
ontogeny to focus the humoral response on con-
served epitopes on the viral hemagglutinin (HA).
The unmutated common ancestors (UCAs) of six
distinct, broadly neutralizing antibody lineages from
one individual bind the HA of a virus circulating at
the time the participant was born. HAs of viruses
circulating more than 5 years later no longer bind
the UCAs, but mature antibodies in the lineages
bind strains from the entire 18-year lifetime of the
participant. The analysis shows how immunological
memory shaped the response to subsequent influ-
enza exposures and suggests that early imprinting
by a suitable influenza antigen may enhance likeli-
hood of later breadth.
INTRODUCTION
Influenza virus in humans evolves in response to pressure from
immunity in the susceptible population, leading to progressive
variation of viral antigenicity. Introduction of a new strain of influ-
enza A from birds or swine (‘‘antigenic shift’’) initiates a cycle of
antibody generation and viral escape (‘‘antigenic drift’’), the latter
largely through mutation of surface residues on the viral hemag-
glutinin (HA) but secondarily through variation of antigenic deter-
minants on the neuraminidase (NA). Detailed antigenic analysis of
annual HA variation in H1 and H3 subtypes shows a punctuated2842 Cell Reports 13, 2842–2850, December 29, 2015 ª2015 The Auevolutionary trajectory, with a shift in ‘‘antigenic cluster’’ (defined
by reactivity with standard panels of ferret immune sera) every
few years (Smith et al., 2004; Fonville et al., 2014). Strong selec-
tive pressure fromwidespread immunity in the human population
thus appears to require more than one seasonal cycle.
The humoral response within individuals also evolves, through
immune memory and B cell affinity maturation. When stimulated
by a new exposure (infection or vaccination), memory cells can
re-enter germinal centers and undergo new rounds of somatic
hypermutation and selection (Victora and Nussenzweig, 2012;
De Silva and Klein, 2015). The net effect of this on-going selec-
tion across the entire population exposed to the virus is a vi-
rus-immunity ‘‘arms race.’’ Mutated HA with reduced affinity
for a particular antibody can, in principle, select for mutations
in the latter that restore strong binding. We can study this evolu-
tionary process by detecting B cells descended from the same
common ancestor and determining the sequences of their rear-
ranged variable-domain genes (Moody et al., 2011).
Antigenic variation requires an annual revision of vaccine com-
ponents. A more effective vaccine strategy would protect
against many rounds of this seasonal variation and ideally
against introduction of new serotypes from viruses circulating
in animal reservoirs (a so-called ‘‘universal’’ influenza vaccine;
Burton et al., 2012; Krammer and Palese, 2015). Broad protec-
tion will probably come from a humoral response to conserved
sites on the viral HA. The two relatively invariant epitopes so
far recognized are the receptor binding site (RBS) on the HA
‘‘head’’ and a surface along the HA ‘‘stem’’ (Knossow et al.,
2002; Ekiert et al., 2009; Sui et al., 2009; Corti et al., 2011;Whittle
et al., 2011; Corti and Lanzavecchia, 2013). Study of over 100
influenza (subtype H1) RBS-directed antibodies from three indi-
viduals, all of whom received the trivalent influenza vaccine in
2008 (Moody et al., 2011), has shown that antibodies engage
the RBS through contacts that recapitulate many of those
made by the viral receptor, sialic acid (Weis et al., 1988; Whittle
et al., 2011; Schmidt et al., 2015). The key interactions come
from a critical dipeptide (valine-aspartic acid or a relatedthors
Figure 1. Timeline of Seasonal H1 Influ-
enzas and Lineage UCA Reactivity
(A) H1 influenza strains from 1977 to 2009 used in
this study. TIV01 birth and administration of the
vaccine are marked.
(B) Six RBS-directed lineages (Lin) with their VH
and VL genes listed. The seasonal strains and year
of isolation (in parentheses) are on the left. KD
values for the Fab binding to monomeric HA heads
are in mM. The ‘‘heatmap’’ color scheme is
arbitrary, as an aid in visualization; warm colors are
high-affinity interactions (e.g., values <1 mM–
15 mM in red) and cool colors are lower-affinity
interactions (e.g., values 60–75 mM in blue); color
changes represent 15 mM intervals; affinities
marked as >100 mM are those beyond the limit of
detection.
See also Figures S1 and S3.sequence) at the tip of the third heavy-chain complementarity
determining loop (CDR H3). This class of antibodies is nearly un-
restricted in VH and VL gene usage; moreover, the lineages show
that distinct affinity maturation pathways can lead from a single
germline precursor (the unmutated common ancestor [UCA]) to
functionally similar outcomes. Many of these antibodies came
from one individual (designated TIV01); they defined various
clonal lineages, each with a unique germline precursor. A suit-
able set of three or four such antibodies would have in common
only contacts with conserved, receptor-interacting amino acid
residues. We proposed that this sort of polyclonal response
would approximate the broad immunity to H1 subtypes that a
universal vaccine should elicit.
We have chosen six lineages of H1 RBS-directed antibodies
from TIV01 and studied the binding of their UCAs and intermedi-
ates with members of a panel of HAs from viruses that circulated
since that individual was born.We find that the UCAs of all six lin-
eages bind the RBS of an H1 virus circulating in the year of
TIV01’s birth (1990), but not the RBS of viruses circulating more
than5 years later. Certain early intermediates bind the initial strain
more tightly, consistent with affinity maturation during a primary
response; affinities of later intermediates and the ‘‘mature’’ anti-
bodies from plasmacytes 7 days post-vaccination indicate affin-
ity maturation during a secondary response. The lineages gained
breadth as they developed, and antibodies from the plasma cells
stimulated by the vaccine had not lost affinity for the 1990 strain.
The results show that we can study the virus-immunity arms race
in humans by sampling an appropriate cohort of individuals and
that we can reconstruct patterns of B cell affinity maturation in
those individuals. They further suggest that very early exposure
to viral antigens may bias subsequent responses.
RESULTS
TIV01 Immune History and RBS-Directed Lineages
TIV01 was 18 at the time of the 2008 study and reported no pre-
vious vaccination history. We prepared a panel of HA1 head do-Cell Repmains fromH1 strains circulating in various years since 1990 and
examined their affinities for the UCAs of antibodies in six lineages
of RBS-directed antibodies (Figures 1A and S1). The average VH-
gene mutational frequency of all the RBS-directed antibody line-
ages isolated from TIV01 was 5%, greater than the likely level
of somatic hypermutation during a primary response (Figures
S2A and S2B). We infer that the antibodies identified in the day
7 samples represent a recall response. Mutation could have
occurred because of an influenza virus infection sometime
between 1990 and 2006 and also during the response to the vac-
cine. The initial screen had no bias for HA binding: of the 404
paired sequences recovered from the entire cohort of five indi-
viduals at day 7, 252 were positive (by ELISA) for at least one
HA in the panel tested (Moody et al., 2011), and Figures S2A
and S2B show that at least 90% of the 174 HA-positive anti-
bodies that came from TIV01 had somatic mutation levels
greater than 2.5%. Thus, not only were the lineages we analyzed
part of a secondary response but also the vast majority of all
antibodies with detectable HA affinity. A similar analysis of line-
ages from other individuals in the same cohort also shows an
almost exclusively secondary response (Figure S2C). The six
chosen lineages represent three different VH genes and five
different VL genes (three Vk and two Vl) and a total of 54 mature
antibodies (Figure 1B). Among the lineages we analyzed is the
broadly neutralizing antibody lineage 860, which includes the
well-characterized antibodies, CH65 and CH67 (Whittle et al.,
2011; Schmidt et al., 2013, 2015; Xu et al., 2015).
Germline Precursors Bind an Early Seasonal Influenza
All six UCAs bound A/Massachusetts/1/1990, which was iso-
lated in the year TIV01 was born (Figure 1B). They also bound
A/Florida/2/1993, but most had low affinities for HAs from vi-
ruses isolated after 1995, and all failed to bind HAs from 1999
onward. In no case did the UCA of the lineages bind the H1
A/Solomon Islands/03/2006 included in the vaccine. The loss
of affinity corresponds accurately to the ‘‘antigenic cartography’’
of H1N1 strains (Bedford et al., 2014). Viruses between 1986 andorts 13, 2842–2850, December 29, 2015 ª2015 The Authors 2843
Figure 2. Properties of Clonal Lineage 860
(A) Phylogenetic tree of lineage 860.
(B) Sequence alignment of VH and VL domains for clonal members. CDR 1 (blue), 2 (pink), and 3 (green) are highlighted; (.) denotes conservation in reference to
the UCA.
(C) Summary of nucleotide (nt) and amino acid (aa) changes in VH and VL. The percent somatic hypermutation (SHM) for the mature antibodies is listed.
See also Figures S2 and S4.1995 belonged to the same antigenic cluster; A/Beijing/262/
1995 was a transition to the 1999–2005 cluster that included
A/New Caledonia/20/1999. The concordance suggests that,
during the course of the decade, seasonal influenza viruses
had evolved resistance to similar antibodies present in the gen-
eral population. This conclusion is consistent with an analysis of
H3N2 antigenicity from 1968 to 2003, which showed that substi-
tutions around the rim of the RBS determined the principal anti-
genic changes during that time period (Koel et al., 2013) and
hence that antibodies binding in or near the RBS were wide-
spread enough to exert strong selective pressure.
Viral Resistance to RBS-Directed Germline Precursors
The one difference between all HAs that bind these UCAs and
those that do not is the loss, in 1995, of residue K133a at the
edge of the receptor-binding pocket. Deletion of K133a from
A/Massachusetts/1/1990 eliminates detectable binding by all
six UCAs; insertion of K133a into A/Solomon Islands/03/2006
generates moderate-to-high affinity for four of the six (Figure S3).
We conclude that viruses that had lost K133a escaped infectivity
neutralization by antibodies such as those studied here and that
the presence of this residue was a principal determinant of
neutralization susceptibility.
The germline origins of the six antibody lineages have in com-
mon only JH6, which encodes a string of tyrosines immediately
C-terminal to the critical dipeptide at the tip of CDRH3.Hydrogen
bonds between K133a and the phenolic hydroxyls are probably
present in many of the UCA-bound complexes. Whereas the
UCAs appear dependent on K133a, subsequent affinity matura-
tion to an immunogen during a secondary exposure has appar-
ently made the antibody response independent of its presence.
Affinity Maturation of RBS-Directed Clonal Lineages
We examined initial steps of affinity maturation in three of the lin-
eages (Figures 2, 3, and 4) bymeasuring binding of early interme-2844 Cell Reports 13, 2842–2850, December 29, 2015 ª2015 The Audiates to the 1990 A/Massachusetts and 1993 A/Florida HAs
(Figure 5). In lineage 860, somatic mutations encoding three
amino acid residues, all in the heavy chain, accumulated be-
tween the germline response and intermediate antibody I-2.
Because neither Fab had detectable affinity for A/Solomon
Islands/03/2006, we concluded in a previous paper that fixation
of the three mutations must have come from enhanced affinity of
I-2 for the virus that induced the primary response (Schmidt
et al., 2013). Indeed, the data in Figure 5 show that I-2 binds
the putative primary antigen (i.e., some strain between 1990
and 1993) substantially more tightly than does the UCA. The
limited number of mutations between UCA and I-2 did not, how-
ever, impart increased breadth, which presumably came from
mutations fixed by exposure to later strains (Figure S4).
In lineage 1277, increased affinity for A/Massachusetts/1/
1990 occurred at the first assignable intermediate, with little af-
finity gain through two additional intermediates to the contempo-
rary antibody (Figures 3 and 5). Those later intermediates did
have successively greater affinities for A/Solomon Islands/03/
2006, however, perhaps driven by a post-1995 strain that had
lost K133a. The earliest intermediates in lineages 1277 and 687
both bind A/Solomon Islands/03/2006 with moderate affinity,
and hence, each lineage has acquired some degree of breadth
even with only four- and three-amino-acid residue changes,
respectively (Figures 3 and 4). We have drawn similar conclu-
sions from the more detailed structural and biophysical analyses
we have carried out on lineages 641, 643, and 652, which will be
the subjects of a separate paper.
The UCAs of the six lineages studied had no detectable affinity
for the year 2008 trivalent inactivated vaccine HA immunogens,
but they all bound tightly with HAs likely to be close relatives of
the eliciting viral antigen. Thus, the affinity increase inferred
from binding measurements with only the vaccine immunogen
overestimates the gain in response to any single exposure,
when the course of affinity maturation has involved successionthors
Figure 3. Properties of Clonal Lineage 1277
(A) Phylogenetic tree of lineage 1277.
(B) Sequence alignment of VH and VL domains for the clonal members. CDR 1 (blue), 2 (pink), and 3 (green) are highlighted; (.) denotes conservation in reference to
the UCA.
(C) Summary of nt and aa changes in VH and VL. The percent SHM for the mature antibodies is listed.
See also Figure S2.of mutated immunogens. We note that the affinities measured
here are for monomeric Fabs and that dimeric IgGs (or IgMs)
will show stronger differential effects.
Breadth of RBS-Directed Clonal Lineages
The UCAs of the six lineages bind HAs only from H1 strains iso-
lated around 1990, but a representative, affinity-matured anti-Figure 4. Properties of Clonal Lineage 687
(A) Phylogenetic tree of lineage 687.
(B) Sequence alignment of VH and VL domains for clonal members. CDR 1 (blue),
the UCA.
(C) Summary of nt and aa changes in VH and VL. The percent SHM for the matur
See also Figure S2.
Cell Repbody (or late intermediate) from each of the six lineages binds
with high affinity to nearly all seasonal H1 HAs in a panel covering
the period from 1977 to 2008 (Figure 6). These lineages illustrate
how an initially restricted response can broaden after encoun-
tering an antigenically distinct HA, if there is a shared, conserved
epitope such as the RBS. The enhanced breadth extends even to
H1 viruses circulating before 1990: matured antibodies in all six2 (pink), and 3 (green) are highlighted; (.) denotes conservation in reference to
e antibodies is listed.
orts 13, 2842–2850, December 29, 2015 ª2015 The Authors 2845
Figure 5. Affinity Maturation of Clonal Lineages
Biolayer interferometric analysis of binding by members of lineage 860 (A),
lineage 1277 (B), and lineage 687 (C) to three H1 seasonal isolates—Massa-
chusetts (MA) (1990), Florida (FL) (1993), and Solomon Islands (SI) (2006). KD
values (mM) are highlighted in gray; immediately below are the ka (10
3M1ms1)
and koff (10
2 s1) values, respectively, that we used to obtain KD.
See also Figure S3.
2846 Cell Reports 13, 2842–2850, December 29, 2015 ª2015 The Aulineages bind more tightly to the 1977 and 1986 strains than do
their respective UCAs.
DISCUSSION
The changing antigenicity of circulating influenza viruses and the
spectra of human serological responses have been the subjects
of an extensive literature since the 1930s (Davenport et al., 1953;
Jensen et al., 1956; Kim et al., 2009; Li et al., 2012, 2013; Hens-
ley, 2014). By 1960, T. Francis, Jr. could write, based on serolog-
ical observations, that ‘‘the antibody which is first established
continues to characterize.[an age] cohort of the population
throughout its life’’ and designated the phenomenon by the
colorful phrase ‘‘original antigenic sin’’ (OAS). Subsequent ob-
servations of a strong serum response to the most-recent ex-
posure appeared at odds with this interpretation, but a contem-
porary analysis has shown that the highest serological titers in a
large, unvaccinated, Vietnamese cohort were indeed for viruses
that circulated when the person was young (mean age about 6
years), the likely time frame of a first infection, but that the
increases in antibody titers immediately following a new infection
were for recent strains (Fonville et al., 2014). Thus, early expo-
sure dominated the steady-state profile, whereas recent infec-
tion determined the immediate response.
Lineage analysis, structures, and affinities of clonally related
human antibodies, lineage intermediates, and their UCAs with
HAs of viruses circulating during the lifetime of the donor have
now allowed us to relate the dynamics of memory, recall, and so-
matic hypermutation to the previous serological characteriza-
tions. The results of this ‘‘immuno-viral archeology’’ show that
RBS-directed antibodies from TIV01 lineages amplified by the
short-term (7-day) response to vaccination bound strongly to
HAs from most of the potential previous exposures but that their
UCAs dated to the earliest exposure and lost affinity as the virus
mutated. That is, even the immediate post-exposure response,
although it had highest affinity for the most-recent strains, de-
scended from the first encounter. A large majority of the anti-
bodies from the TIV cohort, including antibodies with epitopes
other than the RBS, had somatic mutation levels high enough
to indicate a recall rather than primary response (Figures S2B
and S2C), consistent with the published results of several related
studies (Wrammert et al., 2011; Jackson et al., 2014; Tan et al.,
2014). The antigenic distance, irrespective of epitope, between
influenza virus isolates from well-separated time points thus ap-
pears to be within a range that strongly favors recall, consistent
with less direct inference from serological data (Fonville et al.,
2014). Thus, successive influenza virus infections or vaccina-
tions ‘‘update’’ an existing repertoire, at least for relatively
conserved epitopes such as the RBS, but do not appear to
add many new components.thors
Figure 6. Breadth in RBS-Directed Clonal Lineages
Antibodies from clonal lineages assayed for binding to H1 influenzas. KD
values are for Fabs and expressed in mM. The heatmap color scheme is
arbitrary: see legend to Figure 1.Detecting the likely eliciting HA (or a close relative) resolves a
puzzle in our previous work on these and other influenza anti-
body lineages from various subjects. The low affinity of the
UCAs for the vaccine immunogen has seemed to imply a weak
threshold for the binding needed to activate the originating, naive
B cell. We recognized that the extent of somatic hypermutation
indicated a recall response, but we have not had until now an
estimate for the HA affinity required to initiate a germinal center
reaction. The dissociation constants for the Fab-HA head inter-
actions reported here correspond, of course, to lower affinities
than those expected for a trimeric HAwith a dimeric B cell recep-
tor (IgM or IgG). For example, in cases for which we can compare
the dissociation constant (Kd) for Fab-head binding with an avid-
ity estimate from ELISA measurements for the corresponding
IgGs and immobilized HAs, we find half-maximal binding from
the latter experiments that are lower than the monomer-mono-
mer Kds by between two and three orders of magnitude. The
binding of a Fab to a monomeric head is a direct way to relate af-
finity changes to the structural consequences of mutations in the
Fab, because avidity effects, which can depend on the details of
the measurement, are difficult to normalize. We have in practice
found an excellent correlation between avidity, as measured by
ELISAwith HA or with head, and affinity of Fab for head, as deter-
mined here (M. Kuraoka, A.G.S., T. Nojima, D. Kitamura, S.C.H.,
T.B.K., and G. Kelsoe, unpublished data).
Somatic hypermutation and fixation of mutations over a period
of 18 years, presumably by exposure to viruses that had evolved
resistance to one ormore of the earlier antibodies in the lineages,
follows the course expected for co-evolution of influenza virus
and responding human antibodies. Determination of single-
genome HIV glycoprotein sequences from infected individuals
participating in longitudinal studies and concomitant B cell line-
age analyses have enabled studies of theHIV antibody arms race
as it plays out in a single person (Liao et al., 2013; Fera et al.,
2014). A more-complex relationship dictates influenza virus
and human humoral immunity co-evolution, which proceeds by
episodic exposure (from vaccination or occasional infection) of
an individual immune system to antigen and continuous expo-
sure of the circulating virus to herd immunity (Figure 7). Nonethe-
less, our results suggest that it should be possible to carry out
studies of the arms race between influenza virus and the collec-
tive immune response of the sampled population.Cell RepExposure of TIV01 to anH1 influenza virus circulating during in-
fancy (1990–1993) elicited B cell memory that dominated the
response to a trivalent vaccine administered in 2008 (Moody
et al., 2011). More than 60% of the heavy-chain variable regions
cloned from sorted B cells taken 7 days post-vaccination have
the sequence hallmarks of RBS-directed antibodies, and 50%
belong to one of the six lineages studied here. The large number
of distinct lineages of RBS-directed antibodies found in TIV01 is
unusual, however. Whereas RBS-directed antibodies may be
relatively common (Schmidt et al., 2015), other individuals prob-
ably have at most one or two, making antigenic drift toward resis-
tance possible. Indeed, the data in Figure 6 show that, by 2008, a
circulating virus (A/NorthCarolina/AF1292/2008) no longer bound
antibodies from four of the six lineages. One objective for an
improved influenza vaccine might be to increase the frequency
of multiple RBS-directed antibodies in a large enough fraction of
a population to hinder accumulation of such mutant viruses.
The observations reported here are consistent with the notion
that viral antigens seen very early in life, as an infant’s immunity
develops, pre-condition subsequent responses by biasing the
memory repertoire more strongly that do antigens first seen at
later times. This outcome would be similar to imprinting of the
B cell response to bacterial antigens by the early intestinal micro-
biome, as seen in experiments with mice (Hooper et al., 2012). In
a recently published study of a donor who received the 2011
trivalent vaccine, four different day 7 antibodies that neutralized
the A/California/07/2009 component of the vaccine also neutral-
ized the A/USSR/90/1977 isolate, suggesting priming by a strain
closely related to the 1977 virus (Huang et al., 2015). The epitope
recognized by those antibodies is on the head but in a surface
patch well separated from the RBS. The A/USSR/90/1977 virus,
which represents influenza viruses circulating during the donor’s
childhood, was also the first reappearance of a seasonal H1 after
its displacement by H2 in 1957. It would have been the earliest
H1 strain that the donor could have seen. The published study
did not include analysis of the properties of the UCAs of the
day 7 antibodies, as we have done here for the six RBS-directed
lineages from TIV01, and any inference that the germline precur-
sors of the antibodies in that work would recognize the 1977
strain is indirect. Nonetheless, its results suggest that our
findings from TIV01 apply more broadly, as they come from an
individual over a decade older, who received a different trivalent
vaccine, and they involve a different epitope.
The concept of ‘‘B cell lineage vaccine design’’ underliesmuch
of current research on vaccines for HIV, influenza, and other
rapidly evolving pathogens (Haynes et al., 2012; Jardine et al.,
2015). This approach assumes (1) that dominant responses to
exposed, variable epitopes outcompete broadly neutralizing,
subdominant responses to more cryptic, conserved epitopes
and (2) that within the naive B cell repertoires of most individuals
in a population are cells that can respond to those conserved
epitopes when appropriately stimulated. A stimulus that might,
in principle, increase the likelihood of eliciting an otherwise sub-
dominant response is a modified immunogen that binds with
high affinity to the UCA of a lineage with broadly neutralizing po-
tential. In the lineages studied here, the apparent priming stim-
ulus was infection with a seasonal strain during the year after
the person was born, with potential boosts from subsequentorts 13, 2842–2850, December 29, 2015 ª2015 The Authors 2847
Figure 7. Co-evolution of Virus and Anti-
body Response
Left column: episodic exposure to influenza virus
governs evolution of the antibody response (elic-
iting naive response and maturing that response
by affinity maturation in germinal centers). Center
column: essentially continuous selection for mu-
tations that escape host immunity governs evolu-
tion of viral epitopes targeted by protective anti-
bodies in the population as a whole. Right column:
collective immunity is an aggregate of many indi-
vidual responses. The data presented in this paper
suggest that a small number of individual re-
sponses may be enough to give a representative
sample of the population response. Punctuated
evolution of influenza HA antigenicity, docu-
mented for both H1 andH3 influenzas (Smith et al.,
2004, Bedford et al., 2014), defines chronologi-
cally successive antigenic clusters; the color
change in the ‘‘virus’’ icon from blue to red sym-
bolizes a shift from one cluster to the next.
Increasing color intensity of the antibody icons
represents increased affinity.exposures between 1993 and 2008 and a known one from the
2008 vaccine. The boost(s) led to further affinity maturation,
with development of increased breadth; analysis of the interme-
diates in certain lineages suggests where affinity maturation to
the primary exposure ceased and where the secondary expo-
sure(s) took over. Our observation, that early exposure appears
to have biased immunological memory in this individual, sug-
gests that vaccination of infants with HA immunogens selectively
exposing conserved epitopes might be a constructive step to-
ward a vaccine that elicits long-lasting immunity.
EXPERIMENTAL PROCEDURES
Subjects
TIV01 was recruited at Duke University and given the trivalent inactivated sea-
sonal influenza vaccine (TIV) 2007–2008 containing A/Solomon Islands/3/20062848 Cell Reports 13, 2842–2850, December 29, 2015 ª2015 The Authors(H1N1), A/Wisconsin/67/2005 (H3N2), and B/
Malaysia/2506/2004, as described previously
(Liao et al., 2009; Moody et al., 2011).
Lineage Analysis
The lineages analyzed here have been described
and characterized previously (Moody et al., 2011;
Schmidt et al., 2015). The phylogenic tree for
each clone was estimated using the dnaml pro-
gram from Phylip 3.69 package, and the UCA
was obtained by aligning the inferred sequence
at the root to germline gene libraries. The tree
was then recomputed with the UCA at the root,
and the sequences of intermediates at branch
points in that tree were inferred as described (Kep-
ler, 2013). The degree of somatic hypermutation
was such that we found no ambiguity in assigning
from the IMGT database the alleles and se-
quences for heavy-chain V, D, and J and light-
chain V and J. The only potential uncertainties
were at the V-D and D-J boundaries in the heavy
chain, where residues encoded by potential n
nucleotides cannot be derived from genome se-quences. Five of the six clones had so few mutations in CDR H3 that the in-
ferred UCA sequences were unambiguous; for the sixth (641), we followed
the analysis in Moody et al. (2011). If the UCA sequence (the root of the tree)
and sequences of the day 7 antibodies (the twigs of the tree) are known,
then the inferred sequences of intermediates are essentially unambiguous.
Paired-chain sequence used in the original study ensures correct assignment
of the heavy- and light-chain combination.Expression and Purification of HA
All rHA ‘‘head’’ constructs were cloned into pFastBac vector for insect cell
expression. All contained a cleavable C-terminal His6X tag and were purified
from supernatants by passage over Co-NTA agarose (Clontech) followed by
gel filtration chromatography on Superdex 200 (GE Healthcare) in 10 mM
Tris-HCl, 150mMNaCl at pH 7.5. The tagwas removed using PreScission pro-
tease (MolBioTech; ThermoScientific) and the protein repurified using Co-NTA
agarose to remove the protease, tag, and non-cleaved protein. All mutations
were made using QuikChange Mutagenesis (Agilent).
Fab Expression and Purification
The genes for the heavy- and light-chain variable domains were synthesized
and codon optimized by Integrated DNA Technologies or GenScript and
subcloned into protein expression vectors containing human heavy- and
light-chain constant domains. All heavy-chain constructs contained a non-
cleavable His6X tag. Fabs were produced by transient transfection in
HEK293T cells using Lipofectamine 2000 (Invitrogen). Supernatants were har-
vested 5 days later, clarified by centrifugation, and the Fabs were purified us-
ing Co-NTA agarose (Clontech) followed by gel filtration chromatography on
Superdex 200 (GE Healthcare). The buffer purification buffer was 10 mM
Tris-HCl, 150 mM NaCl at pH 7.5. All constructs were confirmed by DNA
sequencing at the DNA Sequencing Core Facility at Dana Farber Cancer
Institute.
Interferometry and Binding Experiments
Interferometry experiments were performed using a BLItz instrument (forte-
BIO; Pall). Purified Fab was immobilized on a Ni-NTA biosensor, and cleaved
rHA headswere titrated to obtain binding kinetics and affinities.KD valueswere
obtained by applying a 1:1 binding isotherm using vendor-supplied software
under the ‘‘Advanced Kinetics’’ program. UCA binding was tested at an initially
high protein concentration of rHA head (75 mM); for detectable binding, rHA
was then titrated at three different concentrations (chosen depending on the
apparent KD from the high concentration); a global fit to the titration curves
was applied to obtain the KD. For mature antibodies, a single high concentra-
tion (25 mM)was used to obtain an approximateKD value. All experiments were
performed in 10 mM Tris-HCl, 150 mM NaCl at pH 7.5 and at room
temperature.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and can be found with this
article online at http://dx.doi.org/10.1016/j.celrep.2015.11.063.
AUTHOR CONTRIBUTIONS
A.G.S. and S.C.H. designed research; A.G.S., K.T.D., K.R.M., T.B.K., H.-X.L.,
and M.A.M. performed research; A.G.S., K.T.D., K.R.M., T.B.K., H.-X.L.,
M.A.M., B.F.H., and S.C.H. analyzed data; and A.G.S. and S.C.H. wrote the
paper.
ACKNOWLEDGMENTS
We thank members of the S.C.H. laboratory for discussions. The work at Har-
vard Medical School and Boston Children’s Hospital was supported by NIH
grant P01-AI089618. S.C.H. is an investigator of the Howard Hughes Medical
Institute.
Received: October 6, 2015
Revised: November 6, 2015
Accepted: November 18, 2015
Published: December 17, 2015
REFERENCES
Bedford, T., Suchard, M.A., Lemey, P., Dudas, G., Gregory, V., Hay, A.J.,
McCauley, J.W., Russell, C.A., Smith, D.J., and Rambaut, A. (2014). Inte-
grating influenza antigenic dynamics withmolecular evolution. eLife 3, e01914.
Burton, D.R., Poignard, P., Stanfield, R.L., and Wilson, I.A. (2012). Broadly
neutralizing antibodies present new prospects to counter highly antigenically
diverse viruses. Science 337, 183–186.
Corti, D., and Lanzavecchia, A. (2013). Broadly neutralizing antiviral anti-
bodies. Annu. Rev. Immunol. 31, 705–742.
Corti, D., Voss, J., Gamblin, S.J., Codoni, G., Macagno, A., Jarrossay, D., Va-
chieri, S.G., Pinna, D., Minola, A., Vanzetta, F., et al. (2011). A neutralizing anti-
body selected from plasma cells that binds to group 1 and group 2 influenza A
hemagglutinins. Science 333, 850–856.Cell RepDavenport, F.M., Hennessy, A.V., and Francis, T., Jr. (1953). Epidemiologic
and immunologic significance of age distribution of antibody to antigenic var-
iants of influenza virus. J. Exp. Med. 98, 641–656.
De Silva, N.S., and Klein, U. (2015). Dynamics of B cells in germinal centres.
Nat. Rev. Immunol. 15, 137–148.
Ekiert, D.C., Bhabha, G., Elsliger, M.A., Friesen, R.H., Jongeneelen, M.,
Throsby, M., Goudsmit, J., and Wilson, I.A. (2009). Antibody recognition of a
highly conserved influenza virus epitope. Science 324, 246–251.
Fera, D., Schmidt, A.G., Haynes, B.F., Gao, F., Liao, H.X., Kepler, T.B., and
Harrison, S.C. (2014). Affinity maturation in an HIV broadly neutralizing B-cell
lineage through reorientation of variable domains. Proc. Natl. Acad. Sci.
USA 111, 10275–10280.
Fonville, J.M., Wilks, S.H., James, S.L., Fox, A., Ventresca, M., Aban, M., Xue,
L., Jones, T.C., Le, N.M., Pham, Q.T., et al. (2014). Antibody landscapes after
influenza virus infection or vaccination. Science 346, 996–1000.
Haynes, B.F., Kelsoe, G., Harrison, S.C., and Kepler, T.B. (2012). B-cell-line-
age immunogen design in vaccine development with HIV-1 as a case study.
Nat. Biotechnol. 30, 423–433.
Hensley, S.E. (2014). Challenges of selecting seasonal influenza vaccine
strains for humans with diverse pre-exposure histories. Curr. Opin. Virol. 8,
85–89.
Hooper, L.V., Littman, D.R., and Macpherson, A.J. (2012). Interactions be-
tween the microbiota and the immune system. Science 336, 1268–1273.
Huang, K.Y., Rijal, P., Schimanski, L., Powell, T.J., Lin, T.Y., McCauley, J.W.,
Daniels, R.S., and Townsend, A.R. (2015). Focused antibody response to influ-
enza linked to antigenic drift. J. Clin. Invest. 125, 2631–2645.
Jackson, K.J., Liu, Y., Roskin, K.M., Glanville, J., Hoh, R.A., Seo, K., Marshall,
E.L., Gurley, T.C., Moody, M.A., Haynes, B.F., et al. (2014). Human responses
to influenza vaccination show seroconversion signatures and convergent anti-
body rearrangements. Cell Host Microbe 16, 105–114.
Jardine, J.G., Ota, T., Sok, D., Pauthner, M., Kulp, D.W., Kalyuzhniy, O., Skog,
P.D., Thinnes, T.C., Bhullar, D., Briney, B., et al. (2015). HIV-1 VACCINES.
Priming a broadly neutralizing antibody response to HIV-1 using a germline-
targeting immunogen. Science 349, 156–161.
Jensen, K.E., Davenport, F.M., Hennessy, A.V., and Francis, T., Jr. (1956).
Characterization of influenza antibodies by serum absorption. J. Exp. Med.
104, 199–209.
Kepler, T.B. (2013). Reconstructing a B-cell clonal lineage. I. Statistical infer-
ence of unobserved ancestors. F1000Res. 2, 103.
Kim, J.H., Skountzou, I., Compans, R., and Jacob, J. (2009). Original antigenic
sin responses to influenza viruses. J. Immunol. 183, 3294–3301.
Knossow, M., Gaudier, M., Douglas, A., Barre`re, B., Bizebard, T., Barbey, C.,
Gigant, B., and Skehel, J.J. (2002). Mechanism of neutralization of influenza vi-
rus infectivity by antibodies. Virology 302, 294–298.
Koel, B.F., Burke, D.F., Bestebroer, T.M., van der Vliet, S., Zondag, G.C., Ver-
vaet, G., Skepner, E., Lewis, N.S., Spronken, M.I., Russell, C.A., et al. (2013).
Substitutions near the receptor binding site determine major antigenic change
during influenza virus evolution. Science 342, 976–979.
Krammer, F., and Palese, P. (2015). Advances in the development of influenza
virus vaccines. Nat. Rev. Drug Discov. 14, 167–182.
Li, G.M., Chiu, C., Wrammert, J., McCausland, M., Andrews, S.F., Zheng, N.Y.,
Lee, J.H., Huang, M., Qu, X., Edupuganti, S., et al. (2012). Pandemic H1N1
influenza vaccine induces a recall response in humans that favors broadly
cross-reactive memory B cells. Proc. Natl. Acad. Sci. USA 109, 9047–9052.
Li, Y., Myers, J.L., Bostick, D.L., Sullivan, C.B., Madara, J., Linderman, S.L.,
Liu, Q., Carter, D.M., Wrammert, J., Esposito, S., et al. (2013). Immune history
shapes specificity of pandemic H1N1 influenza antibody responses. J. Exp.
Med. 210, 1493–1500.
Liao, H.X., Levesque, M.C., Nagel, A., Dixon, A., Zhang, R., Walter, E., Parks,
R., Whitesides, J., Marshall, D.J., Hwang, K.K., et al. (2009). High-throughput
isolation of immunoglobulin genes from single human B cells and expression
as monoclonal antibodies. J. Virol. Methods 158, 171–179.orts 13, 2842–2850, December 29, 2015 ª2015 The Authors 2849
Liao, H.X., Lynch, R., Zhou, T., Gao, F., Alam, S.M., Boyd, S.D., Fire, A.Z., Ros-
kin, K.M., Schramm, C.A., Zhang, Z., et al.; NISC Comparative Sequencing
Program (2013). Co-evolution of a broadly neutralizing HIV-1 antibody and
founder virus. Nature 496, 469–476.
Moody, M.A., Zhang, R., Walter, E.B., Woods, C.W., Ginsburg, G.S., McClain,
M.T., Denny, T.N., Chen, X., Munshaw, S., Marshall, D.J., et al. (2011). H3N2
influenza infection elicits more cross-reactive and less clonally expanded
anti-hemagglutinin antibodies than influenza vaccination. PLoS ONE 6,
e25797.
Schmidt, A.G., Xu, H., Khan, A.R., O’Donnell, T., Khurana, S., King, L.R., Man-
ischewitz, J., Golding, H., Suphaphiphat, P., Carfi, A., et al. (2013). Preconfigu-
ration of the antigen-binding site during affinity maturation of a broadly neutral-
izing influenza virus antibody. Proc. Natl. Acad. Sci. USA 110, 264–269.
Schmidt, A.G., Therkelsen, M.D., Stewart, S., Kepler, T.B., Liao, H.X., Moody,
M.A., Haynes, B.F., and Harrison, S.C. (2015). Viral receptor-binding site anti-
bodies with diverse germline origins. Cell 161, 1026–1034.
Smith, D.J., Lapedes, A.S., de Jong, J.C., Bestebroer, T.M., Rimmelzwaan,
G.F., Osterhaus, A.D., and Fouchier, R.A. (2004). Mapping the antigenic and
genetic evolution of influenza virus. Science 305, 371–376.
Sui, J., Hwang, W.C., Perez, S., Wei, G., Aird, D., Chen, L.M., Santelli, E., Stec,
B., Cadwell, G., Ali, M., et al. (2009). Structural and functional bases for broad-
spectrum neutralization of avian and human influenza A viruses. Nat. Struct.
Mol. Biol. 16, 265–273.2850 Cell Reports 13, 2842–2850, December 29, 2015 ª2015 The AuTan, Y.C., Blum, L.K., Kongpachith, S., Ju, C.H., Cai, X., Lindstrom, T.M., So-
kolove, J., and Robinson, W.H. (2014). High-throughput sequencing of natively
paired antibody chains provides evidence for original antigenic sin shaping the
antibody response to influenza vaccination. Clin. Immunol. 151, 55–65.
Victora, G.D., and Nussenzweig, M.C. (2012). Germinal centers. Annu. Rev.
Immunol. 30, 429–457.
Weis, W., Brown, J.H., Cusack, S., Paulson, J.C., Skehel, J.J., and Wiley, D.C.
(1988). Structure of the influenza virus haemagglutinin complexed with its re-
ceptor, sialic acid. Nature 333, 426–431.
Whittle, J.R., Zhang, R., Khurana, S., King, L.R., Manischewitz, J., Golding, H.,
Dormitzer, P.R., Haynes, B.F., Walter, E.B., Moody, M.A., et al. (2011). Broadly
neutralizing human antibody that recognizes the receptor-binding pocket of
influenza virus hemagglutinin. Proc. Natl. Acad. Sci. USA 108, 14216–14221.
Wrammert, J., Koutsonanos, D., Li, G.M., Edupuganti, S., Sui, J., Morrissey,
M., McCausland, M., Skountzou, I., Hornig, M., Lipkin, W.I., et al. (2011).
Broadly cross-reactive antibodies dominate the human B cell response
against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med. 208,
181–193.
Xu, H., Schmidt, A.G., O’Donnell, T., Therkelsen, M.D., Kepler, T.B., Moody,
M.A., Haynes, B.F., Liao, H.X., Harrison, S.C., and Shaw, D.E. (2015). Key mu-
tations stabilize antigen-binding conformation during affinity maturation of a
broadly neutralizing influenza antibody lineage. Proteins 83, 771–780.thors
